Tocilizumab =========== Injection 162 mg in 0.9 mL single use pre-filled syringe SaveGeneral schedule PBS item code15421PMaximum quantity4 units Repeats6 More detailsProgramGE AdministrationINJECTION Benefit typeS Brands - Avtozma Dispensed price for maximum quantity (DPMQ)3 pricesAvtozma · Community pharmacy$760.99 Avtozma · Private hospital$735.10 Avtozma · Public hospital$715.84 Restrictions & indications ------------------------------ Streamline authority code19020 Giant Cell Arteritis (Active) - Continuing treatment Show full PBS criteriaHide full PBS criteriaActive giant cell arteritis Continuing treatment Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND The treatment must not exceed 52 weeks in total including initial and continuing applications; AND Must be treated by a rheumatologist, clinical immunologist or neurologist experienced in the management of giant cell arteritis. Notes (3)A patient may only qualify for PBS-subsidised treatment under this restriction once in a lifetime. No increase in the maximum quantity or number of units may be authorised. No increase in the maximum number of repeats may be authorised. Prescribing notes (3)No increase in the maximum quantity or number of units may be authorised. No increase in the maximum number of repeats may be authorised. A patient may only qualify for PBS-subsidised treatment under this restriction once in a lifetime. Other listings for Tocilizumab Injection 162 mg in 0.9 mL single use pre-filled syringe --------------------------------------------------------------------------------------- [General12102YMaximum 4 units · 0 repeats - Systemic Juvenile Idiopathic Arthritis - Balance of supply for Initial treatment - Initial 1 (new patient) or Initial 2 (retrial or recommencement of treatment after a break of less than 12 months) or Initial 3 (recommencement of treatment after a break of more than 12 months) - in a patient of any weight being administered a subcutaneous form of this biological medicine](/p/12102Y)[General11748HMaximum 4 units · 1 repeats - Juvenile Idiopathic Arthritis (Active, Severe) - Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply - Juvenile Idiopathic Arthritis (Active, Severe) - Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - Juvenile Idiopathic Arthritis (Active, Severe) - Initial treatment - Initial 1 (new patient) - Juvenile Idiopathic Arthritis (Active, Severe) - Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)](/p/11748H)[General12105DMaximum 4 units · 1 repeats - Systemic Juvenile Idiopathic Arthritis - Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months in a patient weighing less than 30 kg) - Systemic Juvenile Idiopathic Arthritis - Initial treatment - Initial 1 (new patient weighing less than 30 kg) - Systemic Juvenile Idiopathic Arthritis - Initial treatment - Initial 3 (recommencement of a new treatment cycle after a break of more than 12 months in a patient weighing less than 30 kg)](/p/12105D)[General12768BMaximum 4 units · 1 repeats - Juvenile Idiopathic Arthritis (Active, Severe) - Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab)](/p/12768B)[General11720WMaximum 4 units · 2 repeats - Juvenile Idiopathic Arthritis (Active, Severe) - Continuing treatment](/p/11720W)[General12086DMaximum 4 units · 2 repeats - Systemic Juvenile Idiopathic Arthritis - Continuing treatment in a patient weighing less than 30 kg](/p/12086D)[General13301CMaximum 4 units · 2 repeats - Juvenile Idiopathic Arthritis (Active, Severe) - Continuing treatment](/p/13301C)[General10951JMaximum 4 units · 3 repeats - Rheumatoid Arthritis (Severe Active) - Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) - Rheumatoid Arthritis (Severe Active) - Balance of supply - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - Rheumatoid Arthritis (Severe Active) - Initial treatment - Initial 1 (new patient) - Rheumatoid Arthritis (Severe Active) - Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)](/p/10951J)[General11741YMaximum 4 units · 3 repeats - Juvenile Idiopathic Arthritis (Active, Severe) - Initial treatment - Initial 1 (new patient) - Juvenile Idiopathic Arthritis (Active, Severe) - Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - Juvenile Idiopathic Arthritis (Active, Severe) - Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) - Juvenile Idiopathic Arthritis (Active, Severe) - Balance of supply - Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after break of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)](/p/11741Y)[General12095NMaximum 4 units · 3 repeats - Systemic Juvenile Idiopathic Arthritis - Initial treatment - Initial 3 (recommencement of treatment after a break of more than 12 months in a patient weighing at least 30 kg) - Systemic Juvenile Idiopathic Arthritis - Initial treatment - Initial 1 (new patient weighing at least 30 kg) - Systemic Juvenile Idiopathic Arthritis - Initial treatment - Initial 2 (retrial or recommencement of treatment after a break of less than 12 months in a patient weighing at least 30 kg)](/p/12095N)[General12762QMaximum 4 units · 3 repeats - Juvenile Idiopathic Arthritis (Active, Severe) - Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab)](/p/12762Q)[General12806BMaximum 4 units · 3 repeats - Rheumatoid Arthritis (Severe Active) - Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab)](/p/12806B)[General15445XMaximum 4 units · 3 repeats - Rheumatoid Arthritis (Severe Active) - Initial treatment - Initial 1 (new patient) - Rheumatoid Arthritis (Severe Active) - Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) - Rheumatoid Arthritis (Severe Active) - Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)](/p/15445X)[General15446YMaximum 4 units · 3 repeats - Rheumatoid Arthritis (Severe Active) - Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab)](/p/15446Y)[General10954MMaximum 4 units · 5 repeats - Rheumatoid Arthritis (Severe Active) - First continuing treatment - balance of supply - Rheumatoid Arthritis (Severe Active) - First continuing treatment](/p/10954M)[General11730JMaximum 4 units · 5 repeats - Juvenile Idiopathic Arthritis (Active, Severe) - First continuing treatment - Juvenile Idiopathic Arthritis (Active, Severe) - Balance of supply - Continuing treatment - Juvenile Idiopathic Arthritis (Active, Severe) - Subsequent continuing treatment](/p/11730J)[General11743CMaximum 4 units · 5 repeats - Giant Cell Arteritis (Active) - Initial treatment](/p/11743C)[General12099TMaximum 4 units · 5 repeats - Systemic Juvenile Idiopathic Arthritis - Continuing treatment in a patient weighing at least 30 kg](/p/12099T)[General13685GMaximum 4 units · 5 repeats - Rheumatoid Arthritis (Severe Active) - Subsequent continuing treatment](/p/13685G)[General15432FMaximum 4 units · 5 repeats - Juvenile Idiopathic Arthritis (Active, Severe) - Subsequent continuing treatment](/p/15432F)[General11721XMaximum 4 units · 6 repeats - Giant Cell Arteritis (Active) - Continuing treatment](/p/11721X) Data source: [Australian Government PBS Schedule](https://www.pbs.gov.au/info/browse/download) · Record updated 30 September 2026. Verify current listing and prescribing requirements on the [official PBS website](https://www.pbs.gov.au/).